PRRX1 and pulmonary fibrosis: To evaluate the involvement of PRRX1 TFs in pulmonary fibrosis in vivo, we then chose to treat wild type mice with a third generation antisense LNA-modified oligonucleotide (ASO) targeting both Prrx1 isoforms by an endotracheal route to target specifically the lung.